INTRODUCTION

Inflammatory bowel diseases (IBDs) are chronic disabling gastrointestinal disorders affecting every aspect of the affected person’s life, and account for substantial costs to the health-care system and society.1 With the growing number of patients with IBD and cases of hospitalization, the overall medical care cost consequently increases considerably. The annual hospitalization cost per patient, cost per hospitalization, and daily cost during hospitalization have increased significantly in the past decade (all P<0.001).2 The increased hospitalization costs of IBD patients may be associated with biologics use, length of hospital stay, medical insurance, subtypes of IBD, prognostic factors, surgery, and endoscopy.2

The cost of caring for IBD patients is high, with the annual mean cost of around US $6,000 to US $8,000 for CD patients, and US $4,000 to US $5,000 for UC patients in Germany (2006–2007) and the United States (2003–2004).3,4 Results from a large European inception cohort study, enrolling 1,321 patients with IBD diagnosed from October 1991 to September 1993, showed that the mean annual total expenditure on health care was €1,871 per patient-year (equating to approximately US $2,476 per patient-year) for IBD.5 The most expensive aspects were medical and surgical hospitalizations, together accounting for 63% of the cost in CD and 45% in UC.

Recent studies demonstrated that the use of anti–tumor necrosis factor (TNF) therapy may be associated with a reduced need for surgery and hospitalization, as well as an improvement in the quality of life and work productivity in
both CD and UC patients. There is an apparent shift in cost profile from surgery and hospitalization toward anti-TNF treatment; however, the relatively consistent overall costs suggest that the high costs of these drugs are partly compensated for by a reduction in surgery and hospitalization rates.

Without government support, the cost burden of caring for IBD patients will unavoidably rest on the patients and their family. However, if the government will provide full support, it will place a large financial burden on the health-care systems of the country. With the increasing incidence and prevalence of IBD, as well as the use of more and more biologics and state-of-the-art techniques in treating or monitoring IBD patients, how and to what extent public medical insurance support affects current IBD management becomes a practical issue. In this report, we compare the differences in public medical insurance systems for IBD patients among Asian countries, and try to build a basis for understanding the differences and limitations in treating IBD patients among different countries.

METHODS

Questionnaires were designed to gather (i) general, (ii) diagnosis, (iii) treatment, (iv) disease monitoring, and (v) management information, as well as to inquire about the availability of public health systems, the costs of medical, diagnostic, and endoscopy expense, and the coverage rate of biologics use. The questionnaires were sent to IBD experts in each of the Asian countries studied. The results were summarized according to feedback from the responders. The summarized results were returned for review and approval by the responding IBD experts from each country.

RESULTS

We collected responses from Japan (Dr. Tadakazu Hisamatsu), South Korea (Dr. Hyun-Soo Kim), China (Dr. Bayasi Guleng), Hong Kong (Dr. Siew C. Ng), Singapore (Dr. Khoon Lin Ling), Malaysia (Dr. Ida Hilmi), and India (Dr. Vineet Ahuja) in June 2014. The responses were combined with the results from Taiwan, and summarized as the overall results for this report.

1. General Information

As shown in Table 1, the public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore but low in Malaysia and India. Patients
could consult a gastroenterologist or colorectal surgeon by either the walk-in or referral system for the diagnosis and treatment of their IBD in all of these countries. A registration system is available in Taiwan, Japan, South Korea, and Hong Kong. In these countries, registered IBD patients could obtain good support from the government, with their own expenses for treatment being zero (Japan) to minimal (Taiwan, South Korea, and Hong Kong). In Singapore, the copayment rate ranges from 10% to 90%. In Malaysia, payment for general care is low and does not include biologics. In India, most patients are treated in private service hospitals, with the patients themselves shouldering the entire medical expense.

2. Diagnosis

As shown in Table 2, among the diagnostic endoscopy methods, capsule endoscopy is the most expensive (from US $500 to US $2,800), except in Japan where the cost of capsule endoscopy is covered by the government. The most common tool for diagnosing IBD, ileocolonoscopy, was mostly free except in Singapore (about US $750) and India (about US $100).

3. Treatment

As summarized in Table 3, conventional therapies (5-aminosalicylic acid, steroid, immunomodulators) are paid for by

---

Table 2. Comparison of the Cost for IBD Diagnostic Tools in Asia

| Diagnosis (in US dollars) | Taiwan | Japan | South Korea | China | Hong Kong | Singapore | Malaysia | India |
|---------------------------|--------|-------|-------------|-------|-----------|-----------|----------|-------|
| Endoscopy                 | Free   | Free  | 10% of US dollars 50/50 | Free | Free | 300 | Free to minimal charge | 50 |
| Colonoscopy               | Free   | Free  | 10% of US dollars 80/50 | Free | Free | 750 | Free to minimal charge | 100 |
| Small bowel scope        | Free except the over tube | Free | 700–1,200 | Co-pay | Free except the over tube | Free to minimal charge | 100 |
| Over tube                 | 630–1,200 | 600 | 130 | 400 | 1,000–2,500 | Free to minimal charge | 200 |
| Anesthesia                | 100–500 | Free | Free | Free | extra | Free to minimal charge | Extra |
| Capsule endoscopy         | 1,500 | Free | 700 | 565 | 2,000 | 1,800 (public); 2,800 (private) | 1000 | 500 |
| CT/MRI                    | Free   | Free  | 10% of 160 (CT)/ 600 (MRI) | Free | Free | 500–1,000 | Free to minimal charge | 200 |

EGD, esophagogastroduodenoscopy.

Table 3. Comparison of the Cost for IBD Treatment in Asia

| Treatment (annual cost: US dollars) | Taiwan | Japan | South Korea | China | Hong Kong | Singapore | Malaysia | India |
|-------------------------------------|--------|-------|-------------|-------|-----------|-----------|----------|-------|
| 5-ASA                               | Free   | Free  | 10% co-pay | Free | Free | 600–1,200 | 1,000–1,500, free for civil servants | 50 |
| Steroid                             | Free   | Free  | 10% co-pay | Free | Free | 300–600 | Free for civil servants, minimal charge for paying patients | 10 |
| Azathioprine                        | Free   | Free  | 10% co-pay | Free | Free | 600–1,200 | 300 USD for paying patients, free for civil servants | 50 |
| TNF-α antibody                      | Approved: free | Not approved: 17,000 | Free | 15,000 | Approved: free | 25,000 | 20,000 for paying patients, pay and claim back for civil servants | 20,000–22,000 |

5-ASA, 5-aminosalicylic acid; TNF, tumor necrosis factor.
public health insurance in Taiwan, Japan, China, and Hong Kong; in Korea, a 10% copayment system is established. Conventional therapies are paid for by patients in Singapore, Malaysia, and India, and the cost is higher in Singapore than in India. In Japan, biologics are paid for by the government, without a need for prior approval and without a time limitation. In South Korea, patients are responsible for a 10% copayment for biologics. In Taiwan and Hong Kong, the use of biologics needs to be approved in advance to be eligible for a reimbursement. Patients have to pay for biologics in China, Singapore, Malaysia (except civil servants), and India. The cost is between US $15,000 to US $25,000 per patient per year.

4. Monitoring

Tests for complete blood cell count, CRP, ESR, and serum biochemistry for the follow-up of IBD patients are covered by the government or minimally paid for by the patients in all of the countries studied (Table 4). Fecal calprotectin test is available in clinical practice in Singapore and India, costing about US $40 to US $80. It is available for research purposes in Taiwan, Japan, South Korea, and Malaysia; however, it is not yet available in China and Hong Kong. Tests for TNF-α antibody titer and the antibody to TNF-α antibody are not yet available in all these countries.

5. Risk Management

Hepatitis B screening is covered by public health insurance in Taiwan, Japan, China, Hong Kong, and Malaysia. In South Korea, Singapore, and India, patients themselves have to pay for hepatitis B screening (US $10–25). Mycobacterium tuberculosis screening and monitoring are bundled with TNF-α treatment in Taiwan; covered by the government in Japan; and paid for by patients in South Korea (10% copayment), China, Hong Kong, Singapore, Malaysia, and India (US $50–260). Thiopurine S-methyltransferase (TPMT) genotyping/activity and thiopurine metabolite assays are only available in India and cost about US $100. Vaccination programs are free for registered IBD patients in Taiwan, as well as in China and Hong Kong. In other countries, patients have to pay for vaccination (Table 5).

6. Possible Impact

The above results are in line with the previous reports stating that the cost is mostly related to medical expenses, especially biologics. We hypothesized that the percentages of IBD patients taking biologics would be different between countries with a high and those with a low public health coverage. Indeed, we found that the percentage of CD patients treated with biologics was as high as 30%–40% in Japan, where the government covers all expenses for IBD patients. The per-
as low as 1% for CD patients in India, where most of the patients have to pay for the biologics themselves (Table 6).

As reports on mortality results are available only from Japan and Taiwan, and biologics only became available for clinical use in Taiwan in 2008, it might be too early to draw any conclusion about public health insurance–related mortality in IBD patients in these Asian countries.

**DISCUSSION**

From this survey, we found that there were differences in the public health insurance systems among Asian countries. This probably affected the proportion of patients who need to be treated with more expensive medications such as the biologics. Japan and India are the two extremes for this situation. The percentage of IBD patients taking biologics is highest in Japan, where the payment for the diagnosis, treatment, and monitoring of IBD is entirely covered by the government. In contrast, the percentage of IBD patients taking biologics is lowest in India, where the coverage rate by public health insurance is low and IBD patients have to pay for most of their medical expenses. As biologics have been proven to improve the clinical and mucosal status of IBD patients, determining whether the difference will affect the outcomes (such as operation rate, admission rate, or even mortality rate) needs a longer period of follow-up.

This report has some limitations. First, not all IBD experts in the Asian countries studied replied to the survey. Second, those who did reply were limited in number, and thus might not be representative of the true situation in each country. Third, no surgical rate, admission rate, and mortality results were available from all the countries. Therefore, this report could function as an initial report providing background information for understanding the differences in the treatment of IBD patients among countries in Asia.

In summary, this is the first report to compare the public health insurance systems in Asia, especially focusing on IBD-related diagnosis and treatment. The effect derived from the differences needs a longer period of observation to allow making a firm conclusion.

**ACKNOWLEDGEMENT**

The author would like to thanks to Dr. Tadakazu Hisamatsu, Dr. Hyun-Soo Kim, Dr. Bayasi Guleng, Dr. Siew C. Ng, Dr. Khoon Lin Ling, Dr. Ida Hilmi, Dr. Vineet Ahuja, and Dr. Chun Jen Ooi for their great input to this study.
REFERENCES

1. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322-337.

2. Xu J, Tang M, Shen J. Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease: a two-center study over the past decade. Gastroenterol Res Pract 2013;2013:267630. doi: 10.1155/2013/267630.

3. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-1913.

4. Prenzler A, Bokemeyer B, von der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 2011;12:273-283.

5. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-728.

6. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut 2011;60:930-936.

7. Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-160.

8. Wei SC, Lin MH, Tung CC, et al. A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol 2013;13:166. doi: 10.1186/1471-230X-13-166.

9. Uno H, Yao T, Matsui T, et al. Mortality and cause of death in Japanese patients with Crohn’s disease. Dis Colon Rectum 2003;46(10 Suppl):S15-S21.